Abstract
Summary
The receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/osteoprotegerin system is dysregulated in hyperparathyroid bone diseases. The introduction of denosumab preceding elective surgery as an alternative option when surgery is not possible immediately.
Introduction
The effects of denosumab on vascular calcification in patients with chronic renal failure and low bone mass have been a subject of interest. Therefore, this investigation aimed to determine the short-term changes in vascular calcification after denosumab treatment using a serial electrocardiography-gated computed tomography (CT) to measure coronary artery calcification (CAC) in patients with secondary hyperparathyroidism (SHPT) and low bone mass.
Methods
This 6-month study enrolled patients with SHPT and low bone mass (T-score < − 2.5) owing to dialysis. The 2 groups administered denosumab at a dose of 60 mg (denosumab group), and conventional treatment (control group) had 21 patients each. All patients underwent CT scans at baseline and at the follow-up examination at 6 months to determine the bone mineral density and CAC.
Results
The control group demonstrated a significant increase in Agatston scores (187.79 ± 72.27) (P = 0.004). However, no significant change was noted in the denosumab group (P = 0.41). In the denosumab group, only the baseline serum alkaline phosphatase levels correlated negatively with changes in the CAC score (P = 0.01); the baseline alkaline phosphatase levels were the deciding biomarkers for non-responsive CAC scores by Berry Criteria after denosumab treatment (P = 0.02). The denosumab group demonstrated significantly increased bone mineral density in the femoral neck and lumbar spine (P < 0.01).
Conclusion
The findings provide evidence that denosumab may suppress the progression of CAC and also regress osseous calcification in severe cases of high bone turnover.
Similar content being viewed by others
Data availability
The datasets used, analyzed, or both during the current study are available from the corresponding author upon reasonable request.
References
(1997) Patient mortality and survival. USRDS. United States Renal Data System. Am J Kidney Dis 30:S86–S106
Bleyer AJ, Russell GB, Satko SG (1999) Sudden and cardiac death rates in hemodialysis patients. Kidney Int 55:1553–1559
(2010) United States Renal Data System USRDS 2010 Annual Data Report: Atlas of end-stage renal disease in the United States
Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR (2000) Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 15:1974–1980
von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273–278
Malluche HH, Blomquist G, Monier-Faugere MC, Cantor TL, Davenport DL (2015) High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis. J Am Soc Nephrol 26:2534–2544
Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K (1996) Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. Circulation 94:1175–1192
Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB (2004) Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 25:629–672
Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis–from clinical observation towards molecular understanding. Osteoporos Int 18:251–259
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268
Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474
Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, Kong YY, Kwon YG (2003) Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kB (RANK) in endothelial cells. J Biol Chem 278:39548–39557
Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235–244
Prolia (denosumab) product monograph. Mississauga, ON, Canada: Amgen Canada Inc. https://www.amgen.ca/products/~/media/1e79aee7d94340df88c3d97f5bb897c3.ashx. Accessed 7 March 2020
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479
Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D (2006) The receptor activator of nuclear factor-kappa B ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 78:35–44
Price PA, June HH, Buckley JR, Williamson MK (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21:1610–1616
Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H, Kostenuik PJ, Erben RG, Lorenz C, Hofbauer LC (2009) Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175:473–478
Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation 117:411–420
Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327–1339
Chou FF, Chen JB, Lee CH, Chen SH, Sheen-Chen SM (2001) Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg 136:1064–1068
Yano S, Sugimoto T, Tsukamoto T, Yamaguchi T, Hattori T, Sekita KI, Kaji H, Hattori S, Kobayashi A, Chihara K (2003) Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Horm Metab Res 35:259–264
Bleyer AJ, Burkart J, Piazza M, Russell G, Rohr M, Carr JJ (2005) Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 46:464–469
Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC, Renn JH (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99:2426–2432
Yeh C, Lin CL, Wu MT, Yen CW, Wang JF (2008) A neural network-based diagnostic method for solitary pulmonary nodules. Neurocomputing 72:612–624
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832
Lehmann N, Erbel R, Mahabadi AA, Rauwolf M, Möhlenkamp S, Moebus S, Kälsch H, Budde T, Schmermund A, Stang A, Führer-Sakel D, Weimar C, Roggenbuck U, Dragano N, Jöckel KH, Heinz Nixdorf Recall Study Investigators (2018) Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf recall). Circulation 137:665–679
Lacativa PG, de Mendonça LM, de Mattos Patrício Filho PJ, Pimentel JR, da Cruz Gonçalves MD, Fleiuss de Farias ML (2005) Risk factors for decreased total body and regional bone mineral density in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Densitom 8:352–361
Ok E, Asci G, Bayraktaroglu S, Toz H, Ozkahya M, Yilmaz M, Kircelli F, Sevinc Ok E, Ceylan N, Duman S, Cirit M, Monier-Faugere MC, Malluche HH (2016) Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol 27:2475–2486
Kang SH, Cho KH, Park JW, Yoon KW, Do JY (2012) Low-calcium dialysate as a risk factor for decline in bone mineral density in peritoneal dialysis patients. Scand J Urol Nephrol 46:454–460
Verberckmoes SC, Persy V, Behets GJ, Neven E, Hufkens A, Zebger-Gong H, Müller D, Haffner D, Querfeld U, Bohic S, De Broe ME, D'Haese PC (2007) Uremia-related vascular calcification: more than apatite deposition. Kidney Int 71:298–303
Goldsmith DJ, Covic A, Sambrook PA, Ackrill P (1997) Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77:37–43
Molina P, Górriz JL, Beltrán S, Vizcaino B, Pallardo LM (2016) Regression of vascular calcification in a parathyroidectomized patient on dialysis with untreated hypocalcemia over 12-year follow-up. Clin Nephrol 86:333–339
Chertow G, Burke S, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252
Acknowledgments
The authors would like to thank the participating nephrology and radiology departments and their personnel, all members of the Kaohsiung Veterans General Hospital who have been instrumental to the data collection, and data entry staff, who make the study possible. The authors are indebted to the Department of Medical Education and Research and Research Center of Medical Informatics at Kaohsiung Veterans General Hospital for assistance with data analysis.
Funding
This study was funded by an operating grant (VGHKS 104-69, 105-80, and 107-117) from Kaohsiung Veterans General Hospital and the Ministry of Science and Technology (MOST 108-2314-B-010-019-MY3).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Chien-Liang Chen, Nai-Ching Chen, Fu-Zong Wu, and Ming-Ting Wu declare that they have no conflict of interest.
Ethical approval
Ethical approval for this pilot study was provided by the independent ethics committee of the Kaohsiung Veterans General Hospital (VGHKS18-CT-19), and written informed consent was obtained from all patients. This study is registered with the ISRCTN registry, number ISRCTN92563400.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chen, CL., Chen, NC., Wu, FZ. et al. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos Int 31, 1507–1516 (2020). https://doi.org/10.1007/s00198-020-05391-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-020-05391-3